Firefly Neuroscience Brings Objective Brain Diagnostics to U.S. Defense Health

A DoW Partnership Puts AI-Powered EEG Inside Military PTSD and TBI Programs

Firefly Neuroscience (Nasdaq: AIFF) is moving into defense healthcare. On March 26, 2026, the company announced a public-private partnership with the U.S. Department of War to deploy its FDA-cleared Brain Network Analytics (BNA) platform for active-duty service members and veterans with PTSD and traumatic brain injury. The platform brings objective, quantitative brain data into a system that has historically relied on subjective screening.

The partnership builds on prior work from Evoke Neuroscience, acquired in May 2025, including earlier engagement with the U.S. Naval Medical Center Camp Lejeune. Terms were not disclosed. Firefly is moving from pilot work into broader institutional use.

A $232 Billion Problem Without Objective Measurement

PTSD and TBI remain major challenges in military medicine. The estimated excess economic burden of PTSD in the U.S. is $232.2 billion, with $42.7 billion tied to the military population. More than 444,000 service members have been diagnosed with TBI since 2000. Despite that scale, diagnosis often still depends on self-reported symptoms.

Firefly’s BNA platform uses non-invasive EEG and cognitive response data to generate biomarker-driven insights, introducing a more objective layer into how these conditions are assessed and managed.

Multiple Catalysts Beyond Defense

The DoW partnership is one piece of a broader build. Recent updates include the identification of brainwave biomarkers that may differentiate ADHD subtypes, continued development of an NVIDIA-powered brain model using proprietary EEG data, and a reported 20-fold expansion in commercial reach across clinics offering ketamine, TMS, and psilocybin therapies.

A Microcap With Validation and Execution Risk

AIFF trades as a microcap, with the volatility that comes with it. The DoW partnership adds a layer of validation and potential non-dilutive revenue, which sets Firefly apart from many early-stage digital health companies that lack institutional traction. Execution remains the key variable. Partnerships need to convert into sustained deployment and recurring revenue.

Firefly is part of the PRISM MedTech Index. We will be watching how this moves from announcement to implementation.